drugset / Trial / NCT00948675

Study of Participants With Advanced Non-Small Cell Lung Cancer

NCT00948675

Phase 3 Completed 361 enrolled Eli Lilly and Company
RandomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to compare the regimens of pemetrexed, carboplatin with pemetrexed maintenance and paclitaxel, carboplatin, bevacizumab with bevacizumab maintenance in participants with Stage IV nonsquamous non-small cell lung cancer.

Timeline

Start
2009-09-01
Primary completion
2013-01-31
Completion
2020-11-06

Drugs

EvaluationDrugModalityDoseRoute
Comparator Bevacizumab Monoclonal antibody 15 mg/kg Intravenous
Subject Carboplatin Small molecule 6 unknown Intravenous
Comparator Paclitaxel Small molecule 200 mg/m2 Intravenous
Subject Pemetrexed Small molecule 500 mg/m2 Intravenous